The FDA has released its guidance document on biosimilar development, stating that this represents its current thinking and may not be the final document. The document was published last week and will be instrumental in the development of biosimilar products in this country. In the
A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept.
Medicare released its list of the most costly medicines presribed in 2013.
Lyme disease is a multisystem disease caused by the spirochete Borrelia burgdorferi. The organism is transmitted through the bite of certain species of blacklegged ticks (Ixodes spp.).
Can TNF inhibitor therapy be withdrawn in RA patients who are in remission? The DRESS trial reports the results of randomized trial of 180 RA patients taking either etanercept or adalimumab. Patients were randomly assigned to either usual care (no dose reduction) or a stepwise increase
May is Arthritis Awareness Month. Arthritis affects an estimated 52.5 million U.S. adults, is a common comorbidity among those with multiple chronic conditions, and is a leading cause of disability in the United States.
An at-risk population of 407 middle-aged overweight women (BMI ≥ 27 kg/m2) without clinical signs of knee osteoarthritis were prospectively studied for 2.5 years and randomized to receive either glucosamine or diet and exercise in a double-blind, placebo-controlled trial.
Calprotectin a major S100 protein, produced by leukocytes is a potential new biomarker for use as it may be more sensitive disease activity changes than conventional acute-phase proteins.
Morning stiffness is a historic feature of RA and may be related to prolonged inactivity or the chronobiology of rheumatoid inflammation. Chronobiology and chronopharmacology are receiving consideration in investigation and RA trial design. Researchers from Maynooth, Berlin, Vienna and
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
